A comparative study of Botulinum toxin type A versus conventional oral therapy as a second-line treatment of diabetic neuropathy

Table 3 Comparison between the different studied periods according to VAS

VAS	VAS 0	VAS 1 week	VAS 4 weeks	VAS 12 weeks	F	p
Duloxetine (n = 10)
Mean ± SD	8 ± 1.1	7.5 ± 1.4	6.3 ± 1.2	5.8 ± 0.9	17.553^*	< 0.001^*
Median (Min.–Max.)	8 (6–9)	7.5 (6–9)	6.5 (4–8)	5.5 (5–7)	17.553^*	< 0.001^*
p₁		1.000	< 0.001^*	0.001^*
Gabapentin (n = 10)
Mean ± SD	7.5 ± 1.1	6.6 ± 1.6	5.7 ± 1.3	5.5 ± 1.1	9.108^*	< 0.001^*
Median (Min.–Max.)	7.5 (6–9)	6.5 (4–9)	6 (4–8)	5 (4–8)	9.108^*	< 0.001^*
p₁		0.112	0.004^*	0.009^*
Botox (n = 10)
Mean ± SD	8.1 ± 0.7	7.3 ± 0.8	5.5 ± 0.8	6.2 ± 1	30.221^*	< 0.001^*
Median (Min.–Max.)	8 (7–9)	7.5 (6–8)	5.5 (4–7)	6 (5–8)	30.221^*	< 0.001^*
p₁		0.019^*	< 0.001^*	0.004^*

SD: standard deviation
F: F test (ANOVA) with repeated measures, Sig. bet. periods was done using post hoc test (adjusted Bonferroni)
p: p value for comparing between the different studied periods
p₁: p value for comparing between VAS 0 and each other period in each group
^*Statistically significant at p ≤ 0.05